Table of Contents
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Fibrosis to Musculoskeletal Disorders Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Fibrosis to Musculoskeletal Disorders Clinical Trials 22
Clinical Trials by Phase in E7 Countries 24
Clinical Trials in E7 Countries by Trial Status 25
Clinical Trials by Phase 26
In Progress Trials by Phase 27
Clinical Trials by Trial Status 28
Clinical Trials by End Point Status 30
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Fibrosis Therapeutics Clinical Trials 35
Prominent Drugs 36
Latest Clinical Trials News on Fibrosis 37
Nov 08, 2019: Forbius completes phase 1 oncology dose-escalation with AVID200, first-in-class TGF-beta 1 & 3 inhibitor: Well tolerated, target inhibition demonstrated at all dose levels, data reported at SITC 37
Oct 31, 2019: Galmed Pharmaceuticals to present new data on aramchol effect on glucose metabolism, MoA and clinical results at AASLD 2019 37
Oct 14, 2019: Forbius completes enrollment into phase 1a solid tumor trial of AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor; Closes Series C Financing 38
Oct 10, 2019: Can Fite announces publication of Namodenoson NASH mechanism of action in International Journal of Molecular Medicine 38
Sep 26, 2019: Galmed Pharmaceuticals initiated ARMOR, a phase 3/4 registrational study of Aramchol in subjects with NASH and fibrosis 38
Clinical Trial Profile Snapshots 40
Appendix 188
Abbreviations 188
Definitions 188
Research Methodology 189
Secondary Research 189
About GlobalData 190
Contact Us 190
Source 191
Fibrosis Therapeutics, Global, Clinical Trials by Region, 2019* 8
Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10
Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12
Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13
Fibrosis Therapeutics Clinical Trials, North America, Top Countries, 2019* 14
Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 15
Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 16
Proportion of Fibrosis to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2019* 18
Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 21
Proportion of Fibrosis to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2019* 23
Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24
Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25
Fibrosis Therapeutics, Global, Clinical Trials by Phase, 2019* 26
Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 27
Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29
Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30
Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31
Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 32
Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34
Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 35
Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 36
List of Figures
Fibrosis Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
Fibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Fibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Fibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12
Fibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13
Fibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14
Fibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 15
Fibrosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 16
Proportion of Fibrosis to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2019* 17
Fibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19
Fibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20
Proportion of Fibrosis to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2019* 22
Fibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24
Fibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25
Fibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2019* 26
Fibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 27
Fibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2019* 28
Fibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2019* 30
Fibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 31
Fibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 32
Fibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 33
Fibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 35
Fibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 36
GlobalData Methodology 189
【免責事項】
https://www.marketreport.jp/reports-disclaimer